Symposia

Arranged in conjunction with key healthcare professionals in the immunotherapy field.

Our symposia are designed to help keep healthcare professionals informed about the latest advancements in ECP. If you missed our symposia in 2023, take a look at the recordings on-demand below.

Upcoming Symposia
Past Symposia

We currently have no upcoming symposia

Filter by:

Oct 24, 2024

COSTEM 2024: Meet The Expert Session

Berlin, Germany

Oct 11, 2024

EORTC 2024 Clinical Symposium: Durability of Response – An important parameter in the management of CTCL

Lausanne, Switzerland

Oct 7, 2024

SITO 2024 Clinical Symposium: Save the Date

Palermo, Italy

Sep 26, 2024

ADO 2024 Clinical Symposium: ECP as monotherapy and combination partner

Würzburg, Germany

Sep 22, 2024

TTS 2024 Clinical Symposium: ECP after solid organ transplantation: Possible role in ABMR and presentation of patient cases

Istanbul, Turkey

Sep 12, 2024

16th International Congress on Lung Transplantation Clinical Symposium: ECP in Lung Transplantation: From treating to preventing – What? How? What for?

Paris, France

Sep 12, 2024

DGTI 2024 Clinical Symposium: ECP best practice and possible future perspectives. This event is in German

Düsseldorf, Germany

Sep 6, 2024

EBMT 9th International Transplant and Cellular Therapy Course Clinical Symposium: 30 years of treating GvHD with ECP

Barcelona, Spain

Apr 16, 2024

EBMT 2024 Nurse Symposium: 30 Years of ECP – Patient-centered therapy using Therakos ECP technology, then, now and in the future

Glasgow, Scotland

View Symposium

Apr 12, 2024

ISHLT 2024 Clinical Symposium: The modern role of ECP in Heart and Lung transplantation: from treatment to prevention

Prague, Czech Republic

View Symposium

Oct 19, 2023

COSTEM 2023: Meet The Expert Session

Berlin, Germany

View Symposium

Oct 19, 2023

Austrotransplant 2023 Clinical Symposium: ECP after solid organ transplantation, possible role in patients with ABMR, infections and high risk patients

Eisenstadt, Austria

Oct 5, 2023

UKPS 2023 Clinical Symposium: To improve overall survival in acute GvHD by applying ECP

London, UK

Sep 23, 2023

6th International Chronic GvHD Clinical Symposium: ECP usage in the real world for cGvHD – Patient cases

Zagreb Croatia

Sep 21, 2023

DGTI 2023 Clinical Symposium: Extracorporeal photopheresis: Collection efficiency of ECP systems - Vascular accesses in the ICU
This event is in German

Berlin, Germany

Sep 8, 2023

ADO 2023 Clinical Symposium: Benefits of ECP alone and in combination for the treatment of CTCL patients. This event is in German

Hamburg, Germany

Sep 8, 2023

EBMT 2023 8th International Transplant Course: Post-transplant – How to treat GvHD with ECP in 2023

Barcelona, Spain

Apr 24, 2023

EBMT 2023 Nurse Symposium: ECP and the GvHD patient journey

Paris, France

View Symposium

Apr 23, 2023

EBMT 2023 Clinical Symposium: Before, during and after transplant – The management of GvHD and the role of ECP

Paris, France

View Symposium

Sep 23, 2022

EORTC 2022 Clinical Symposium: Role of ECP Immunomodulation in current treatment strategies for CTCL

Madrid, Spain

View Symposium

Oct 15, 2021

EORTC 2021 Clinical Symposium:
Role of ECP Immunomodulation in current treatment strategies for CTCL

Marseille, France

View Symposium

Aug 30, 2021

ESOT 2021 Clinical Symposium:
ECP Immunomodulation in SOT: A Role for early intervention?

Milan, Italy

View Symposium

Mar 15, 2021

EBMT 2021 Nurse Symposium:
Therakos ECP Immunomodulation™ – Getting the most out of your service

Virtual Event

View Symposium

Aug 31, 2020

EBMT 2020 Nurse Symposium:
Therakos ECP Immunomodulation™ – How and why

Virtual Event

View Symposium

Sep 17, 2019

ESOT 2019 Clinical Symposium:
Utility and potential of Extracorporeal Photopheresis (ECP) in solid organ transplantation (SOT): Back to the future

Copenhagen, Denmark

View Symposium

EBMT 2024 Highlight Report

DISCOVER MORE

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Symposia

Arranged in conjunction with key healthcare professionals in the immunotherapy field.

COSTEM 2024: Meet The Expert Session

EORTC 2024 Clinical Symposium: Durability of Response – An important parameter in the management of CTCL

SITO 2024 Clinical Symposium: Save the Date

ADO 2024 Clinical Symposium: ECP as monotherapy and combination partner

TTS 2024 Clinical Symposium: ECP after solid organ transplantation: Possible role in ABMR and presentation of patient cases

16th International Congress on Lung Transplantation Clinical Symposium: ECP in Lung Transplantation: From treating to preventing – What? How? What for?

DGTI 2024 Clinical Symposium: ECP best practice and possible future perspectives. This event is in German

EBMT 9th International Transplant and Cellular Therapy Course Clinical Symposium: 30 years of treating GvHD with ECP

EBMT 2024 Nurse Symposium: 30 Years of ECP – Patient-centered therapy using Therakos ECP technology, then, now and in the future

ISHLT 2024 Clinical Symposium: The modern role of ECP in Heart and Lung transplantation: from treatment to prevention

COSTEM 2023: Meet The Expert Session

Austrotransplant 2023 Clinical Symposium: ECP after solid organ transplantation, possible role in patients with ABMR, infections and high risk patients

UKPS 2023 Clinical Symposium: To improve overall survival in acute GvHD by applying ECP

6th International Chronic GvHD Clinical Symposium: ECP usage in the real world for cGvHD – Patient cases

DGTI 2023 Clinical Symposium: Extracorporeal photopheresis: Collection efficiency of ECP systems - Vascular accesses in the ICU This event is in German

ADO 2023 Clinical Symposium: Benefits of ECP alone and in combination for the treatment of CTCL patients. This event is in German

EBMT 2023 8th International Transplant Course: Post-transplant – How to treat GvHD with ECP in 2023

EBMT 2023 Nurse Symposium: ECP and the GvHD patient journey

EBMT 2023 Clinical Symposium: Before, during and after transplant – The management of GvHD and the role of ECP

EORTC 2022 Clinical Symposium: Role of ECP Immunomodulation in current treatment strategies for CTCL

EORTC 2021 Clinical Symposium:Role of ECP Immunomodulation in current treatment strategies for CTCL

ESOT 2021 Clinical Symposium:ECP Immunomodulation in SOT: A Role for early intervention?

EBMT 2021 Nurse Symposium:Therakos ECP Immunomodulation™ – Getting the most out of your service

EBMT 2020 Nurse Symposium:Therakos ECP Immunomodulation™ – How and why

ESOT 2019 Clinical Symposium:Utility and potential of Extracorporeal Photopheresis (ECP) in solid organ transplantation (SOT): Back to the future

EBMT 2024 Highlight Report

Discover more

Courses

Webinars

Speaker Meetings

Ask the Expert

Welcome to the Home of ECP

You are leaving the Therakos.eu website.

Welcome to the Therakos Institute

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

DGTI 2023 Clinical Symposium: Extracorporeal photopheresis: Collection efficiency of ECP systems - Vascular accesses in the ICU
This event is in German

EORTC 2021 Clinical Symposium:
Role of ECP Immunomodulation in current treatment strategies for CTCL

ESOT 2021 Clinical Symposium:
ECP Immunomodulation in SOT: A Role for early intervention?

EBMT 2021 Nurse Symposium:
Therakos ECP Immunomodulation™ – Getting the most out of your service

EBMT 2020 Nurse Symposium:
Therakos ECP Immunomodulation™ – How and why

ESOT 2019 Clinical Symposium:
Utility and potential of Extracorporeal Photopheresis (ECP) in solid organ transplantation (SOT): Back to the future

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS